Skip to Main Content

Paper Details

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.
Immunity
75
2021
K18, SARS, SARS-CoV, SARS-CoV-2, SARS-CoV-2 antibody, SARS2, SARS2-38, anti-SARS-CoV-2 monoclonal antibodies, hACE2, human, human angiotensin converting enzyme-2, mice, receptor binding motif, severe acute respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus 2, spike protein
Author NameAffiliation
Laura A VanBlarganWashington University School of Medicine
Rita E ChenWashington University School of Medicine
Pavlo GilchukVanderbilt University Medical Center
Pei-Yong ShiUniversity of Texas Medical Branch, USA Sealy Institute for Vaccine Sciences
Scott A HandleyWashington University School of Medicine
Adrianus C M BoonWashington University School of Medicine
James E CroweVanderbilt University Medical Center
  • 1 - 7

Datasets

Release 1.2